Reports preliminary GAAP gross margin of 58.9% and Non-GAAP gross margin of 53.4%. Net cash usage in the quarter was $3.3M. The company ended the period with $296.1M of cash, cash equivalents, marketable securities, and restricted cash. “Quanterix (QTRX) continues to build on our strong momentum, achieving our sixth consecutive quarter of double-digit growth. We are pleased to reaffirm our full year 2024 outlook, which is especially notable given the muted growth that continues to impact the tools space,” said Masoud Toloue, CEO of Quanterix. “With a focus on disciplined execution of our strategic priorities, we are expanding the Quanterix portfolio of innovative products and services, empowering our customers to break new ground in research, and lead advancements in Alzheimer’s diagnostics.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on QTRX:
- Quanterix (QTRX) Q3 Earnings Cheat Sheet
- Lucent introduces LucentAD Complete multi-marker blood test
- Closing Bell Movers: IGM Biosciences down 20% on strategic pivot
- Quanterix announces commercialization of p-Tau 217 test kit
- Leerink sees preliminary CLFS determinations as a negative for Quanterix
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
